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Introduction: The German PID-NET registry was founded in 2009, serving as the first
national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of
the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the
registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment
of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36
German PID centres in an online registry. Data was analysed with the software Stata®
and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants.
Among patients aged 1–25, there was a clear predominance of males. The median
age of living patients ranged between 7 and 40 years, depending on the respective
PID. Predominantly antibody disorders were the most prevalent group with 57% of all
2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of
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patients. Familial cases were observed in 21% of patients. The age of onset for presenting
symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms
comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were
diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic
delay, no PID had undergone a slight decrease within the last decade. However,
both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening
the time between onset of symptoms and genetic diagnosis. Regarding treatment,
49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous;
29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one
hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians,
researchers, the pharmaceutical industry, politicians, and ultimately the patients, for
whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Keywords: registry for primary immunodeficiency, primary immunodeficiency (PID), German PID-NET registry, PID
prevalence, European Society for Immunodeficiencies (ESID), IgG substitution therapy, CVID
INTRODUCTION
Primary immunodeficiency disorders (PIDs) represent a group
of more than 350 monogenetic, distinct rare diseases. Due to
the heterogeneity of the different PID, the exact prevalence
is unknown and approximated to be around 1 in 10.000,
Abbreviations: AI, autoimmune disease; ALPS, autoimmune lymphoproliferative
syndrome; APDS, activated PI3K-delta syndrome; APECED, autoimmune
polyendocrinopathy candidiasis ectodermal dystrophy; A-T, ataxia telangiectasia;
ATM, ataxia telangiectasia mutated; CEREDIH, Centre de Référence Déficits
Immunitaires Héréditaires; CID, combined immunodeficiency; CGD, chronic
granulomatous disease; CINCA syndrome, chronic infantile neurologic
cutaneous and articular syndrome; CMC, chronic mucocutaneous candidiasis;
combined ID, combined immunodeficiency; CSR/HIGM, Class-Switch
Recombination defects/Hyper IgM (HIGM) syndromes; CVID, common
variable immunodeficiency; def., deficiency; DGS, DiGeorge syndrome; EBMT
registry, European Society for Blood and Marrow Transplantation Registry; ESID,
European Society for Immunodeficiencies; FCAS, familial cold autoinflammatory
syndrome; FHLH, familial hemophagocytic lymphohistiocytosis syndromes;
FMF, familial Mediterranean fever; G6PD, glucose-6-phosphate dehydrogenase
deficiency; GSD 1b, glycogen storage disease type 1b; HAE (C1inh), hereditary
angioedema (C1 inhibitor); HIES, hyper IgE syndrome; HLA, human leukocyte
antigen; HSCT, hematopoietic stem cell transplantation; IBD, inflammatory
bowel disease; ICF, immunodeficiency centromeric instability facial anomalies;
ID, immunodeficiency; IgA, immunoglobulin A; IgG, immunoglobulin G;
IgM, immunoglobulin M; innate ID, defects in innate immunity; IPEX,
immunodysregulation polyendocrinopathy enteropathy X-linked syndrome;
iv, intravenous; LAD, leukocyte adhesion deficiency; MBL, mannose-binding
lectin; MSMD, mendelian susceptibility to mycobacterial disease; MonoMAC,
monocytopenia and mycobacterial infection; NBS, Nijmegen breakage syndrome;
PFC, properdin P factor complement deficiency; PID, primary immunodeficiency;
PMS2, post-meiotic segregation 2; RALD, Ras-associated lymphoproliferative
disease; SCID, severe combined immunodeficiency; SPAD, deficiency of specific
IgG (specific antibody deficiency); sc, subcutaneous; SCETIDE, Stem Cell
Transplant for primary Immune Deficiencies in Europe; TLR/NFkappa-B, Defects
of Toll-like receptor/nuclear factor of kappa light polypeptide gene enhancer
in B cells 1; TRAPS, TNF-receptor associated periodic fever syndrome; WAS,
Wiskott-Aldrich syndrome; WHIM, warts hypogammaglobulinemia infections
and myelokathexis; XLP, X-linked lymphoproliferative syndrome; XLT (WASP),
X-linked thrombocytopenia with mutations in WASP; WASP, Wiskott-Aldrich
syndrome protein.
(1). With the aim of closing this knowledge gap, the PID-
NET registry (http://www.pid-net.org/) was founded in 2009
by a consortium of researchers from the Arbeitsgemeinschaft
Pädiatrische Immunologie (API, http://www.api-ev.eu/), with
funding support from the German Federal Ministry of Education
and Research (BMBF).
The primary purpose of the registry is to gather data on
the epidemiology, diagnostic delay, diagnosis, and treatment of
PIDs. The secondary aim was to establish a support network
amongst the physicians who treat PID patients in Germany and
other countries across Europe; to enable this, the German PID-
NET registry was placed within the framework of the European
Society for Immunodeficiencies Registry (ESID registry), an
online registry that was created in 2004 and redesigned in June
2014. The objectives of the redesigned version were to make the
documentation process more secure, to provide a more concise
user interface, and to include the definitions of new research
questions on PID. The redesign aimed at reducing the burden
of the documentation process to increase patient capture with
a minimal defined dataset. Investigator-driven more extensive
datasets were encouraged, resulting in 3 levels of registration.
“Level 1” dataset: comprises a minimal set of data (patient’s
background, way to diagnosis (date and type of presenting
symptoms), PID diagnosis, therapy [Immunoglobulin G (IgG)
substitution, hematopoietic stem cell transplantation (HSCT),
gene therapy], and death report, if applicable with the aim of
documenting a complete dataset for each patient once a year.
“Level 2” dataset: for additional information such as
laboratory values, imaging or biopsy results, additional clinical
features, and further treatment details; aims for more details of
the natural history of diseases or disease groups.
“Level 3” dataset: for prospective (clinical) studies on specific
genetic diseases for a defined time-span with a comprehensive,
study-specific dataset.
While each institution participating in the registry agreed
to perform Level 1 registration, Level 2 and 3 registration was
Frontiers in Immunology | www.frontiersin.org 3 July 2019 | Volume 10 | Article 1272
El-Helou et al. German Registry of Primary Immunodeficiency
voluntary depending on availability of data for the given disease,
documentation capacity, and research interests. The registry also
serves both as a platform for publications and a study portal.
German centres participate in national and international studies
such as the unPAD-, CGD-, and APDS-studies (2) (https://esid.
org/Working-Parties/Registry/Studies).
MATERIALS AND METHODS
The German PID-NET registry contains data from patients (with
no age restrictions) in whom a primary immunodeficiency has
been diagnosed according to either ESID registry diagnostic
criteria or genetic diagnosis1. Patients can only be registered
if: (i) the documenting centre has obtained a positive vote
from the local ethics committee; (ii) an agreement between the
treating centre and the ESID has been signed; and (iii) the
patient or his/her guardian has signed the PID-NET/ESID patient
consent form.
Centre Characteristics
There were 34 participating centres in Germany as of July
2017. A centre is defined as one or more departments
within one hospital, or a healthcare centre for which the
ethical approval for PID-NET documentation and an agreement
between ESID and the centre have been signed. Seven of the
participating centres consisted of 2 different departments within
1 hospital (1 for paediatrics and 1 for adults), with locations
in Freiburg, Hannover, Berlin (Charité), Würzburg, Tübingen,
Bonn, and Kiel. Additional centres were located in Munich
(2 hospitals), Leipzig (2 hospitals and 1 healthcare centre),
Frankfurt, Düsseldorf, Ulm, Krefeld, Münster, Dresden, Bochum,
Bremen, Heidelberg, Erlangen, Homburg, Hamburg-Eppendorf,
Sankt Augustin, Stuttgart, Aachen, Dortmund, Rostock, Cologne,
Göttingen, Berlin (2 hospitals), Essen, Halle, and Magdeburg.
The children’s departments in Düsseldorf, Frankfurt, Leipzig
(St. Georg hospital), and Munich (Dr. von Hauner Children’s
Hospital) also treat adult patients, since there is no corresponding
adult department that specializes in the treatment of PID. In
Berlin at the Charité, the children’s department continues to
care for their patients when they reach adulthood, while the
other adult PID patients are treated in the adult department
(Supplementary Table 1).
Ethics Committee Vote
In the Federal Republic of Germany, one of the prerequisites
that can particularly cause delay in the participation of each
centre or hospital department is the requirement for approval
from the local ethics committee. This is in contrast to other
countries such as France, where only one ethics committee vote is
needed for participation of centres/departments across the entire
country. German hospitals without an ethics committee must
apply to their State Chamber of Medicine (Landesärztekammer)
for approval. Once an ethics committee vote is obtained in
1ESID. ESID Registry – Working Definitions for Clinical Diagnosis of PID. Available
online at: https://esid.org/Working-Parties/Registry/Diagnosis-criteria (accessed
August 8, 2017).
Germany, it usually does not expire, except in Erlangen after 5
years and in Tübingen after 3 years.
Technology Platform
The German PID-NET consortium agreed to use the online
database platform provided by ESID for the documentation of
PID patients. In contrast to the UK, PID-NET Germany does not
run a dedicated server for its registry, but directly enters the data
from German PID patients into the ESID registry. Therefore, the
German PID-NET registry forms the subset of the PID patients
entered by German documenting centres into the ESID registry.
Although this renders the German PID-NET registry dependent
on changes performed on the European level, it also ensures
immediate and full implementation of any changes conducted
at the European level. This process is further facilitated by
the fact that coordination of the ESID online registry is also
based at the Centre for Chronic Immunodeficiency (CCI) in
Freiburg, Germany.
A redesigned version of the ESID registry went online in
June 2014 and contained a number of improvements leading
to better data quality: (i) introduction of new datasets, (ii)
implementation of novel categories, (iii) automated quality and
plausibility checks, (iv) separation of the former complex forms
into three levels to achieve a more uniform and complete
documentation, and (v) definitions of clinical criteria in cases
where a genetic defect is yet to be identified2. As an additional
quality check, physicians needed to review the data imported
from the previous version of the ESID registry and add missing
“Level 1” information. The technology platform is described by
Scheible et al. (3).
This process entailed screening the 1,997 PID patients entered
between the year 2004 and 2014, and then transferring only
those marked as “living” and matching the criteria of the new
registry over to the new platform. Each imported dataset had
to be manually checked and ultimately verified. This process
was completed by September 2016 for all 1,404 imported
patients. The introduction of new clinical criteria for PID
led to the reclassification of some patients; for example from
“common variable immunodeficiency (CVID)” to “unclassified
antibody deficiency.”
IT/Data Security
As a yearly update of the registry data is desired, automated
reminders sent by email to users at the documenting centres
have been introduced. Patient data can be entered via a standard
web browser. For secure data transmission, an SSL-protected
internet connection with a security certificate is used. All
medical data (MDAT) are saved on a server within the Secure
Server Net of the computing centre at the University Hospital
Freiburg. To separate identification data from medical data for
security reasons, a second separate server containing the personal
identification data (IDAT) has been established and is operated
by an independent trustee. The data from these two sources is
2ESID. ESID Registry – Working Definitions for Clinical Diagnosis of PID.Available
online at: https://esid.org/Working-Parties/Registry/Diagnosis-criteria (accessed
August 8, 2017).
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only combined for matching names with medical information
by eligible users who have logged into the system with their
personal username and password. A team at the University of
Mainz (https://www.unimedizin-mainz.de/imbei/informatik/ag-
verbundforschung/mainzelliste.html) has previously developed
a tool for pseudonymisation and record linkage (the so-called
Mainzelliste), which was implemented into the ESID registry
in 2014. The TMF e.V. (Technologie- und Methodenplattform
für die vernetzte medizinische Forschung e.V., www.tmf-ev.de)
was consulted for questions relating to programming and data
security for the Mainzelliste. This tool automatically identifies
duplicate entries in the personalized version, as soon as the entry
mask is saved. In such cases, the user receives a message with
the notification specifying the centre in which this patient was
registered before.
Coded vs. Personalized Version
German documenting centres can decide whether they wish
to register their patient’s name, full date of birth, postal code,
and city to the Mainzelliste (personalized version), or whether
they want to omit such details and keep their own patient-list
(coded version). The advantages of using the personalized version
include a reduction in documentation errors such as double
registration or mixing-up of patients, as the user also can see the
name of the patient in the user interface, both in the overview
list and at the top of the screen while checking or entering data.
However, some centres have opted to use the coded version,
mostly due to internal data security policies.
PID Categories and PID Genes
In the PID-NET registry, 153 different PID diagnoses can
be registered, including 11 autoinflammatory disorders. The
different PIDs are classified into 9 main categories and 89
subcategories. Currently, there are 273 PID-causing genes
available for documentation. However, mutations in some of
these genes may cause (up to 6) different PID phenotypes.
Therefore, 104 genes are listed twice or more in the PID overview
list (Supplementary Table 2)3. There is no known monogenetic
cause for 24 of the PIDs; 8 of these are different types of
“unclassified” PIDs.
Medical Documentation Specialist
A key contributor to the coordination and support of all
participating centres in Germanywas themedical documentation
specialist, who was funded by the BMBF betweenNovember 2009
and March 2018. This post served to fulfil a number of tasks:
(i) contacting and recruiting all German centres, (ii) providing
support to each centre for gaining local ethics approval, (iii)
creating user accounts and dispensing passwords, (iv) designing
and creating questionnaires for the registry4, (v) making visits
to centres, training doctors and study nurses, entering data, (vi)
3ESID. ESID Online Registry: Diseases and Genes. Available online at: https://esid.
org/Working-Parties/Registry/New-ESID-Registry/List-of-diseases-and-genes
(accessed August 8, 2017).
4ESID. Registry Working Party. New ESID questionnaires. Available online
at: https://esid.org/Working-Parties/Registry/New-ESID-Registry/New-ESID-
questionnaires (accessed August 8, 2017).
analysis of data with statistical evaluation, (vii) writing abstracts,
reports, publications, and articles, such as for newsletters for the
German support group for primary immunodeficiency dsai e.V.,
and (viii) giving presentations and presenting posters at national
and international meetings.
Since physicians across different German hospitals have
varying degrees of organisation, manpower, time, andmotivation
to register patients, the PID-NET data is either entered by
the treating physician or study nurse, or by the PID-NET
documentation specialist who travels to the centres to support
their efforts.
Center Coverage in Germany
Only a few hospitals in Germany have special departments in
which physicians focus on adult PID patients. There are large
centres for adult PID patients in Freiburg, Hannover, and Berlin.
In addition to hospital care, PID patients often receive treatment
from local physicians, who usually collaborate with a hospital
specialized in treatment of PID. These patients receive their IgG
replacement either at their physician’s private practice or the local
hospital, or they are treated for the symptoms they present with at
the time. In order to join the registry, local physicians also have
to apply for an ethics committee vote from the State Chamber
of Medicine (Landesärztekammer). Besides the administrative
paper work associated with this application, further obstacles
that deter local physicians from joining the PID-NET registry
include the fee for the ethics vote and, in particular, the additional
workload required to lodge an application and enter the data.
Data Set
Patients Background
For our analysis, we used the Level 1 dataset which has to be
completed for every patient in the PID-NET registry and should
be updated yearly. The patient’s background profile contains
basic information about the month (only for children <12 years)
and year of birth (the exact date of birth is not documented
for data protection reasons), country of birth and current
residence, gender, information on twin status, information on
additional familial cases, and potential consanguinity of the
parents. To determine the pathway to diagnosis, we retrieved
the date of the very first clinical diagnosis of PID, based on
laboratory values and/or clinical criteria. The date on which
the patient first presented with PID-related symptoms was
also recorded. Here, it should be taken into account that
onset data are “soft” data, as they depend on the retrospective
recollection of patients, relatives and physicians and are therefore
often subjective.
Way of Diagnosis
To acquire more consistent data on the PID diagnosis, we only
documented patients in whom the clinical diagnostic criteria
from the ESID registry were fulfilled. These criteria are regularly
updated and displayed on the ESID website5. Furthermore,
if applicable, any affected gene(s) as well as the date of the
5ESID. ESID Registry – Working Definitions for Clinical Diagnosis of PID.Available
online at: https://esid.org/Working-Parties/Registry/Diagnosis-criteria (accessed
August 8, 2017).
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genetic diagnosis were documented, along with the name of
the genetic laboratory, the sequencing method [gene sequencing
(Sanger sequencing and gene panels), whole exome/genome
sequencing], and other definitive genetic test (such as 22q11 FISH
for DiGeorge syndrome)], and the reason for genetic testing.
Presenting Symptoms
In contrast to the old ESID online registry, the new version
(since June 2014) contains five pre-defined categories for the
first presenting symptoms of PID: (1) infections; (2) immune
dysregulation such as lymphoproliferation (splenomegaly,
hepatomegaly, lymphadenopathy), granuloma formation,
autoimmunity (e.g., cytopenia, thyroid disease, joint disease,
hepatitis, vitiligo, alopecia, diabetes), inflammatory bowel
disease, celiac disease, vasculitis, eczema, and autoinflammatory
disease; (3) malignancy; (4) syndromal manifestations:
dysmorphic features (such as short stature, facial abnormalities,
microcephaly, skeletal abnormalities) and other organ
manifestations (such as albinism, hair or tooth abnormalities,
heart or kidney defects, hearing abnormalities, primary
neurodevelopmental delay, seizures), and (5) other symptoms.
The last category allowed the entry of free text. For the analysis,
we only included patient data where information was given.
Age Distribution
To determine the distribution of the patients by age, we used
data from patients marked as living (2,242 patients). In order
to obtain the patient’s age, we calculated the year of “last news
from patient” minus the year of birth; the “date of last news” is
defined as the date of the patient’s last visit, or the date where
information was received, e.g., by telephone. This information
was only available for 2,239 patients. In 3 of the patients, data
entry had not yet been completed during the verification process.
For patients aged 1 year or less, we also incorporated the month
into the age calculation. This process then allowed us to refine the
age in 25 out of 53 such patients.
Diagnostic Delay
To determine the general diagnostic delay, we calculated the
time that lapsed between the first presenting symptoms and the
date of either the genetic or clinical diagnosis. If both of these
dates were available, we used the earlier one. To determine the
clinical and genetic diagnostic delays, we calculated the time
that lapsed between the onset of the presenting symptoms and
the date of clinical and genetic diagnosis, respectively. Patients,
that have been “discharged after complete recovery” have been
excluded from this analysis. Possible changes in the diagnostic
delay were analysed using the Jonckheere-Terpstra trend test. A
p-value of 0.05 and below was defined as statistically significant.
When considering the significance of the diagnostic, clinical or
genetic delays, we had to take into account the different number
of patients across different PID categories; these numbers varied
from 2 to up to 527 for a specific PID.
Cause of Death
In order to document the cause of death, we asked for: (i)
date of death, (ii) the main causes leading to death (septic
shock, heart failure, respiratory failure, liver failure, renal
failure, multiple organ failure, haemorrhage, thrombosis,
neurological complications, surgical complications, drug
toxicity, relapse of malignancy, veno-occlusive disorder, graft
vs. host disease, rejection/poor graft function, post-transplant
lymphoproliferative disorder, others), and (iii) underlying
morbid settings associated with mortality (infection, malignancy,
immune dysregulation, transplantation related cause, others).
Multiple answers were possible. For the underlying setting
leading to death, an additional free text description could
be entered optionally. Furthermore, ICD-10 codes could be
entered optionally.
Treatment
IgG substitution, hematopoietic stem cell transplantation
(HSCT), and gene therapy were documented (where applicable).
For IgG substitution, data on the IgG product currently in use
(brand name), dosage, route and place of administration were
requested by the database, along with the patient‘s weight and
side effects at the date of last news or current documentation
date. Side effects such as anaphylaxis, aseptic meningitis, fever,
headache, local side effects (e.g., rash, swelling), renal failure,
arterial thrombosis, and venous thrombosis were provided as
options for selection. For the option “other side effects” (e.g.,
rash, swelling), a free text field was available. Regarding HSCT,
the date of the procedure, the type of donor, source of CD34
stem cells, the SCETIDE ID (Registry for stem cell transplants for
PIDs in Europe—www.scetide.org, in collaboration with ESID),
and the EBMT ID (Registry of the European Society for Blood
and Marrow Transplantation—www.ebmt.org) were requested
by the database. For gene therapy, the date of the gene therapy
had to be entered.
Data Analysis
To generate box plots (Figure 6 and Supplementary Figures 3
and 4) and to calculate p-values, we used Stata R© (StataCorp LP,
USA). MS Excel (Microsoft, USA) software was used for the
remaining statistical analyses.
RESULTS
Registration Progress Since Start of
PID-NET Registry
When the PID-NET registry was founded in March 2009, 630
patients had already been registered by German centres into the
ESID registry. In June 2014, 1,997 patients had been registered
into the old version, 1,404 of which were transferred to the new
registry system. By July 4, 2017 (data lock), 2,453 patients had
been registered. The development of PID patient registration
over the last 9 years is depicted in Figure 1.
Of the 2,453 patients, 2,242 were marked as living, 11 as
discharged after complete recovery, 51 as deceased, and 149 as
lost to follow-up. The 11 discharged patients were diagnosed
with: deficiency of specific IgG (SPAD) (1 patient), IgA with IgG
subclass deficiency (1 patient), isolated IgG subclass deficiency
(3 patients), and transient hypogammaglobulinemia of infancy
(6 patients).
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FIGURE 1 | Registration progress since start of PID-NET registry.
In relation to the 82,576,900 inhabitants of Germany
(2017)6, the 2,242 living PID patients equated to a minimum
PID prevalence of 2.72 per 100,000 inhabitants in Germany.
According to our previous report in March 2012, the minimum
prevalence was calculated as 1.51 per 100,000 inhabitants (4).
There were 2,184 patients (89%) with complete Level 1 data,
i.e., with all fields filled-out for these patients. There were
371 patients (15%) registered at centres that did not enter the
names of their patients (coded version). Centres that used the
Mainzelliste for pseudonymization (personalized version) had a
total of 2,082 (85%) registered patients.
Geographical Distribution
The geographical distribution and participation of PID centres
in Germany in July 2017 is shown on a map in Figure 2,
while the same information from March 2012 can be viewed
in Supplementary Figure 5 (4). Supplementary Table 1 displays
the geographical distribution of PID patients and the growth in
the number of registered patients since our last publication in
2012 (4). The number and distribution of participating centres
within the federal states differed immensely: North Rhine-
Westphalia has 10 documenting centres, while other federal
states only have 1–5 centres. Rhineland-Palatinate and Thuringia
do not have any participating centres to date. Small centres
may have documented only 1 patient, whereas the largest centre
(Freiburg) has 488 documented patients. Of the 2,453 PID
patients, 48 (2%) were born outside Germany.
Most Frequent PIDs and Main PID
Categories
Of the 156 PIDs covered by the registry, only 70 different PIDs
(45%) were documented for patients in Germany. The 12 most
frequent PIDs (each with more than 50 registered patients)
accounted for 74% of all PID patients (n = 1,825). Specifically,
CVID was diagnosed in 728 patients (30%), unclassified antibody
6Statistisches Bundesamt (Destatis). Bevölkerung auf Grundlage
des Zensus 2011. Available online at: https://www.destatis.de/DE/
ZahlenFakten/GesellschaftStaat/Bevoelkerung/Bevoelkerungsstand/Tabellen/
Zensus_Geschlecht_Staatsangehoerigkeit.html (accessed December 5, 2018),
German, English
deficiency in 267 patients (11%), chronic granulomatous disease
(CGD) in 129 patients (5%), agammaglobulinemia in 112
patients (5%), isolated IgG subclass deficiency in 101 patients
(4%), severe combined immunodeficiency (SCID) in 83 patients
(3%), unclassified immunodeficiency in 76 patients (3%),
combined immunodeficiency in 74 patients (3%), selective IgA
deficiency in 69 patients (3%), ataxia telangiectasia (A-T) in
66 patients (3%), DiGeorge syndrome (DGS) in 65 patients
(3%), and hyper IgE syndrome (HIES) in 55 patients (2%)
(Supplementary Table 6).
The cohort distribution according to the main PID category
is shown in Figure 3, and a comparison between patients
registered until March 2012 vs. July 2017 can be seen in the
Supplementary Table 7. We then questioned whether a shift in
percentage had taken place within the main categories of the
Gathmann et al. publication (4) vs. our dataset: The biggest
difference was a decrease of 6% (from 63 to 57%) in the category
of predominantly antibody disorders. Accordingly, combined
immunodeficiencies increased from 4 to 7%, and autoimmune
and immune dysregulation syndromes increased from 3 to
6%. This is possibly due to the fact that more centres had
started documenting children; Another reason could be an
increased knowledge about the genetic basis of PID, resulting
in an increased classification as CID or autoimmune and
immune dysregulation syndromes in patients who had previously
been classified as predominantly antibody disorders (including
CVID). Other groups remained relatively unchanged.
Age and Gender Distribution at Date of
Last News From Patient
The gender of 2,242 living patients was available from the
registry; 997 (44%) of these were female and 1,245 (56%) male.
There was a clear predominance of males amongst patients aged
0–25; however, no statistical differences in gender were found
amongst PID patients >25 years old (Figure 4).
There were 1,010 patients (45%) under the age of 18 and 1,229
patients (55%) aged 18 or older. The oldest registered patient
was an 88-year-old male with CVID. Comparative analysis of the
12 most prevalent PIDs and Wiskott-Aldrich syndrome (WAS),
X-linked lymphoproliferative syndrome (XLP), and familial
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FIGURE 2 | Registered PID-distribution in Germany, July 2017. The size of the circles is proportional to the numbers of patients. In one city there can be one or
multiple centres participating in registering patient data. The base map was adapted with the permission of d-maps.com (https://d-maps.com).
hemophagocytic lymphohistiocytosis syndromes (FHLH) led to
the following results (see also Supplementary Figures 8 and 9):
Age distribution varied within each of the different PIDs
(Table 1): the oldest registered patients (between 68 and 88 years
old) had CVID, unclassified antibody deficiency (80 years old),
unclassified immunodeficiencies (79 years old), selective IgA
deficiency (75 years old), and isolated IgG subclass deficiency
(68 years old). In contrast, the maximum age (years) of patients
who had neither HSCT nor gene therapy was 43 for HIES, 21 for
SCID, 40 for DGS, 37 for A-T, 31 for Wiskott-Aldrich syndrome
(WAS), and 13 for familial hemophagocytic lymphohistiocytosis
syndromes (FHLH).
The age range (years) of living patients who had undergone an
HSCT but no gene therapy was: 8–32 in 7 patients transplanted
for X-linked lymphoproliferative syndrome (XLP) (mean = 21);
0–29 in 51 patients with CGD (mean = 12); 0–28 in 64 HSCT-
transplant patients with SCID (mean = 10); and 51 for CVID
patients (n= 1). The oldest livingHSCT-transplant PID patient is
an XLP patient who underwent a transplant at the age of 32. The
median current age of those who had receivedHSCTwas between
5 (FHLH) and 21 (XLP) (Supplementary Table 10). The median
current age was similar in male vs. female patients, except for
FHLH patients, whose median current age after transplant was
5 years higher in females.
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FIGURE 3 | Main categories of PID based on the IUIS classification of 2,453 patients.
The age of patients (2 SCID patients, 1 CGD patient,
and 2 WAS patients) who had undergone gene therapy was
8 months to 5 years at the time of the first gene therapy.
One patient who received a gene therapy at the age of 8
month received a second gene therapy at the age of 8 years.
Two of these 5 patients also underwent hematopoietic stem
cell transplantation, the CGD patient 5 years and the WAS
patient 7 years after gene therapy (Supplementary Table 11).
For details on age distribution by year of birth, please refer to
Supplementary Figures 53–56.
Gender distribution within the 12 most prevalent PIDs as well
as XLP, WAS, and FHLH is shown in Supplementary Figure 8.
As expected, there were significantly more male patients
with X-linked PIDs: agammaglobulinemia (93% male),
CGD (80%), XLP (93%), WAS (100%), and FHLH (100%)
(Table 1). More detailed information can be seen in
Supplementary Figures 12–33.
We then endeavoured to calculate in living patients with the
12 most prevalent PIDs the median age at which the last news
from patient occurred, and whether this median age differed
across genders.
The highest median age in years of PID patients without
HSCT or gene therapy was 39 in isolated IgG subclass deficiency
patients, and 40 in CVID patients. The median age of patients
with unclassified antibody deficiency was 28. The lowest median
age was found in patients with FHLH (median 7) and DGS
(median 8) (Table 1). The median age of female patients was
generally lower than that of male patients, except in the case of
DGS patients (4 years higher).
Genetics
Out of the 2,453 patients analysed, 893 (36%) had a defined
gene defect, as determined by various genetic tests such as (i)
Sanger sequencing and gene panels (641 patients, 72%), (ii) whole
exome/genome sequencing (22 patients, 2%), and (iii) other
definitive genetic test (65 patients, 7%), for 165 patients (18%),
no information was available. In addition, 58 patients (2%) were
waiting for their genetic test results. In 168 patients (7%), at least
one genetic test was performed, but a suspected mutation was not
identified. We did not asked for precise information on which
genetic test was performed if no mutation had been found. No
genetic testing was conducted in 1,005 patients and there was no
information available in 329 patients. In other words, in the 1,061
patients in whom a genetic test was completed, a mutation was
identified in 84%.
Amongst the 893 PID patients with a genetic defect, 2
(0.2%) were recorded to have been tested neonatally and 9
(1%) prenatally (6 DGS patients with Del 22q11.2, 1 SCID
patient with RAG1 and 1 ALPS patient with a FAS (TNFRSF6)
mutation). Of note, in certain PIDs such as CVID, isolated
IgG subclass deficiency and selective IgA deficiency, physicians
rarely reported genetic testing: Of the 728 patients with CVID,
505 (69%) were marked as not having been genetically tested,
while in 165 patients (23%), there was no information available
about whether or not genetic testing had taken place. However,
amongst the 70 CVID patients for whom genetic testing had
been documented, 21 (30%) were registered with a mutation.
The results of a genetic test were still pending for 9 CVID
patients (11%), while in 49 patients (62%), genetic testing was
carried out, but no disease-causing mutation was identified
(Supplementary Table 34). Mutations were registered in DGS
in 98%, A-T in 95%, CGD in 87%, agammaglobulinemia in
86%, HIES in 84%, and SCID in 76% of patients, respectively
(Supplementary Table 35).
We then aimed to determine which genetic diagnosis
predominates among the various categories and PIDs. We
analysed the main categories and PIDs in which each had at least
20 patients with a genetic defect. It is important to note here
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FIGURE 4 | Age and gender distribution of 2,239 living PID patients at “date of last news”. (A) Living patients with date of last news, (B) Living patients without HSCT
or gene therapy, (C) Living patients with HSCT.
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TABLE 1 | Age range and median age at last news from patient in years of the 12 most prevalent PID diagnoses and WAS, XLP, and FHLH (patients with no HSCT or
gene therapy), living patients.
12 PIDs,
WAS, XLP, FHLH
Male
(n)
Female
(n)
Total
(no HSCT/no gene
therapy)
Age range
(years)
Median age
(years)
Living patients with
and withoutHSCT/
gene therapy
CVID 313 352 665 99.8% 3–88 40 666
Unclassified antibody deficiency 102 119 221 99.1% 0–80 28 223
CGD 46 12 58 51% 0–59 21 114
Agammaglobulinemia 90 7 97 98% 2–54 17 99
Isolated IgG subclass deficiency 40 42 82 100% 4–68 39 82
SCID 6 2 8 11% 0–21 15 76
Unclassified IDs 22 20 42 93% 3–79 20 45
Combined ID 21 17 38 60% 3–57 18 63
DGS 25 27 52 100% 0–40 8 52
Selective IgA deficiency 17 30 47 100% 3–75 23 47
A-T 30 25 55 96% 3–37 13 57
HIES 28 19 47 85% 0–43 16 55
WAS 7 0 7 25% 0–31 20 28
XLP 14 1 15 68% 7–52 19 22
FHLH 3 0 3 17% 2–13 7 18
Total 763 672 1,437 87% 0–88 1,647
that one mutated gene can cause different PIDs, while one PID
can be caused by mutations in several genes. Most genetically-
diagnosed patients had a gene defect in BTK (XLA, 91 patients),
which belongs to the main category of predominantly antibody
disorders, followed by 80 CGD patients with GP91-phox (CYBB)
mutation, which belongs to the phagocytic disorders. Sixty-
four patients had a Del 22q11.2 defect (DiGeorge syndrome),
63 had an ataxia telangiectasia mutated gene (ATM) (A-T),
36 had a STAT3 mutation (Hyper IgE syndromes), 24 had
a WASP mutation [Wiskott-Aldrich syndrome (WAS)]. These
four PIDs belong to the main category other well-defined
PIDs. Twenty-four patients had a MEFV mutation [(familial
Mediterranean fever (FMF)], which belongs to the main category
autoinflammatory disorders, and 20 patients had a defect in C1
Inhibitor (complement deficiency), which belongs to the main
category of complement deficiencies (Table 2).
Two-thirds of the 893 patients with a proven genetic defect
were male (594, 66.5%) and 299 (33.5%) were female. For some
X-linked PIDs, all documented patients were male. This was
true for 24 WAS patients with mutations in WASP, for 19 XLP
patients with mutations in BIRC4/XIAP, for 18 patients with
X-SCID due to mutations in IL2RG, and for 16 patients with
a class switch recombination defect (HIGM syndrome) due to
mutations in CD40L/CD154. In addition, all 7 patients with X-
linked thrombocytopenia due to mutations inWASP were male.
For X-linked gene defects it is normally expected that only
male patients are affected, but there can be exceptions: 1 female
out of 91 patients with agammaglobulinemia [with Turner
syndrome (X,0)] had a monoallelic mutation in BTK, and 1
female out of 10 X-linked lymphoproliferative syndrome (XLP)
patients had a mutation in SH2D1A (XLP1). Furthermore, there
were 77 male patients (96%) and 3 females amongst individuals
with a mutation in GP91-phox (CYBB). Some of the reasons
for females being affected with X-linked traits include skewed
lyonization and Turner Syndrome.
No gender predilection is expected for autosomal traits;
however, we observed a skewed gender distribution for the
following autosomal gene defects: STAT3 (HIES)−64% male,
MEFV (FMF)−63% male, and ATM (A-T)−59% male. The only
genetic PID with female predominance was HAE (C1 Inhibitor),
with 75% females (Supplementary Table 36).
Familial Cases and Consanguinity
Overall, 521 out of 2,453 (21%) patients had a relative with
PID (familial case). These 521 patients came from 403 unrelated
families. Twenty-two of the 521 patients were twins (10 identical
twins, 8 non-identical twins, 4 twins of unknown status).
Amongst the familial cases, 209 (40%) were female and 312
(60%) male.
The highest percentage of these familial cases occurred in
CVID (102 patients, 20%), CGD (40 patients; 8%), unclassified
antibody deficiency (39 patients; 7%), agammaglobulinemia (33
patients; 6%), SCID (25 patients; 5%), HIES (21 patients; 4%) as
well as ALPS and combined ID (each 19 patients, 4%).
We were particularly interested in the proportion of PID
patients with consanguineous parents. We found 186 patients
(8%) who had related parents. From these 186 patients, 74
had a family member with a PID; however, only 21 of these
relatives were registered in the PID-NET registry. Eighteen of
them were siblings and 1 was an uncle/aunt. In 9 patients, it
was noted that the parents were “probably related”; one such
patient had a family member with PID. The highest percentage
of consanguinity occurred in the following main categories: 25%
(44 patients) in combined immunodeficiencies, 16% (7 patients)
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TABLE 2 | Most registered gene defects with corresponding main category, subclass and PID with minimum 20 patients affected.
Gene Main category Subcategory PID Number of
patients
Living Deceased Lost Female Male
BTK* Predominantly
antibody
disorders
Agammaglobulinemia Agammaglobulinaemias 91 86 5 1 90
gp91-phox
(CYBB)*
Phagocytic
disorders
Chronic granulomatous
disease (CGD)
CGD 80 73 4 3 3 77
Del
22q11.2
Other well
defined PIDs
DiGeorge syndrome DGS 64 60 4 33 31
ATM Other well
defined PIDs
DNA-breakage disorder A-T 63 54 6 3 26 37
STAT3 Other well
defined PIDs
Hyper IgE syndromes HIES 36 36 13 23
WASP*§ Other well
defined PIDs
Wiskott-Aldrich
syndrome (WAS)
WAS 24 23 1 24
MEFV Autoinflammatory
disorders
Familial Mediterranean
fever (FMF)
FMF 24 20 4 9 15
P47-phox
(NCF1)
Phagocytic
disorders
Chronic granulomatous
disease (CGD)
CGD 24 22 1 1 10 14
C1
Inhibitor
Complement
deficiencies
Complement deficiency HAE (C1Inh) 20 20 15 5
*Encoded on the X-chromosome. §Mutations in WAPS were also identified in 7 patients with X-linked thrombocytopenia with mutations in WASP (XLT) and in 2 patients with
congenital neutropenia.
in defects of innate immunity, 13% (38 patients) in other well-
defined PIDs, and 13% (26 patients) in phagocytic disorders
(Supplementary Table 37). Interestingly, a high percentage of
familial cases was registered in the main categories with low
consanguinities: e.g., in patients with complement deficiencies,
the respective percentages of patients from non-consanguineous
vs. consanguineous families was 57 vs. 5%; in diseases of immune
dysregulation, 41 vs. 11%; and in autoinflammatory disorders, 31
vs. 8% (Supplementary Table 37 and Supplementary Table 38).
These data suggest that autosomal-dominant traits may prevail
in these particular disorders.
Presenting Symptoms
For 2,153 of the 2,453 PID patients, information on presenting
symptomswas recorded in the registry, including 93 patients with
no presenting symptoms.
Amongst these patients, 1,598 (74%) had infections as
presenting symptoms. The highest rate of infection was
found in patients with CSR/HIGM (Hyper-IgM) syndrome
(32 patients, 97%), CMC (15 patients, 94%), isolated IgG
subclass deficiency (83 patients, 93%), CVID (577 patients,
92%), and agammaglobulinemia (91 patients, 92%); 547 patients
(22%) presented with immune dysregulation. The highest rates
of immune dysregulation were found both in 88% ALPS
patients (30) and 80% patients with unclassified immune
dysregulation (16). There were 190 patients (9%) with syndromal
features, which were most frequent amongst patients with
Nijmegen breakage syndrome (NBS1) (8 patients, 89%) and
DiGeorge syndrome (DGS) (47 patients, 84%). Malignancy
was registered as a presenting symptom in 19 patients
(1%) (Supplementary Table 39): 10 patients had lymphoma
only, 1 had lymphoma and seminoma, 2 had thymoma, 2
had breast cancer only, 1 had an adenocarcinoma, 1 had
multiple carcinoma (squamous epithelial carcinoma, colon
carcinoma, and carcinoma of the prostate), 1 had breast cancer
and multiple carcinoma (adenocarcinoma, squamous epithelial
carcinoma, and squamous epithelial carcinoma), and 1 had acute
lymphoblastic leukaemia.
“Other presenting symptoms” were documented for 248
patients. Ataxia was mentioned 37 times in the 39 patients
with A-T; fever was documented as presenting symptom in 34
patients, of whom 22 had autoinflammatory disorders. Swelling
was entered as presenting symptom in 15 of the 23 patients with
HAE (C1Inh). Based on the registered patient data, we found no
significant gender differences in the kind of presenting symptoms
amongst PID patients.
We then wanted to determine whether there were any
distinctive features in patients for whom no symptoms were
registered. Amongst the 93 asymptomatic patients, 10 (12% of all
SCID patients) had SCID, 10 had unclassified antibody deficiency
(4% of all patients), 8 had CVID (1% of all CVID patients), 6 had
CGD (5% of all CGD patients), 5 had agammaglobulinemia (4%
of all agammaglobulinemia patients), 5 hadHAE (C1Inh) (22% of
all HAE patients), and 5 had transient hypogammaglobulinemia
(24% of all transient hypogammaglobulinemia).
Laboratory abnormalities were identified in 55 out
of the 93 asymptomatic patients. Most of these had
hypogammaglobulinemia (28) or neutropenia (7). In the
same group of asymptomatic patients, 52 had a genetic defect in
a PID-causing gene.
Genetic testing was performed in 29 patients for family
screening and in 14 patients for clinical diagnostic purposes;
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FIGURE 5 | Onset of presenting symptoms.
7 patients had received a prenatal diagnosis of which 5
patients were a familial case and 16 patients were tested for
unknown reasons.
Age of Onset for Various PIDs
Regarding the age of onset for the 12 most common PIDs
[(Figure 5) and Supplementary Table 40], we observed that: (i)
disease onset mainly occurred in the first year of life in patients
with SCID (86%), DGS (82%), HIES (58%), agammaglobulinemia
(47%), and combined ID (44%) (Supplementary Figure 41); (ii)
symptom onsetmainly occurred between the ages of 1–5 amongst
patients with the following PIDs: isolated IgG subclass deficiency
(27%), unclassified IDs (27%), selective IgA deficiency (48%),
CGD (46%), and A-T (87%) (Supplementary Figure 42); (iii) in
addition to the main onset age of 1–5 years, late disease onset was
also often observed in patients with CVID (21%) and unclassified
antibody deficiency (33%) (Supplementary Figure 43).
In two patients, the date of genetic diagnosis preceded the
onset of symptoms, since both had already undergone prenatal
genetic analysis. One ALPS patient with a FAS (TNFRSF6)
mutation was tested prenatally because her brother was already
diagnosed with a PID. Her first symptoms presented 13 months
after birth. The second patient had a Del 22q11.2 mutation
(DiGeorge syndrome) with the first presenting symptoms
occurring during the first year of life (Supplementary Table 44).
In patients with an inborn error of immunity and an
identified gene defect, the first presenting symptoms can still
occur even after the age of 20, e.g., in our cohort, one
patient with agammaglobulinemia due to a BTK mutation first
showed manifestation of the disease at the age of 30, one
patient with CSR/HIGM (Hyper-IgM) due to a PMS2 mutation
showed manifestation at the age of 36, and one patient with
CSR/HIGM (Hyper-IgM) due to a CD40L mutation showed
manifestation at the age of 44. One HIES patient with a
STAT3 mutation showed manifestation of the disease at the
age of 30 and was diagnosed in the following year. Two ALPS
patients with mutations in CD95 (germline - ALPS IA) and FAS
(TNFRSF6) developed their presenting symptoms at the ages of
22 and 25, respectively.
Age at Diagnosis
We next calculated the percentage of PID patients who were
diagnosed before vs. at or after the age of 18. Amongst the 12
most-diagnosed PIDs, the highest percentage (>75%) of patients
diagnosed before the age of 18 were as follows: all 77 SCID
and all 63 A-T patients were actually diagnosed before age of
13 years; 103 patients (95%) with agammaglobulinemia were
diagnosed before age of 18 (no patients were diagnosed between
the ages of 13 and 18) and 5% between the ages of 18 and 44; 60
patients (94%) with DGS and 113 patients (92%) with CGD were
diagnosed before the age of 18. The highest age at which diagnosis
occurred in a CGD patient was 58, in DGS patients 31; 47 patients
(87%) with HIES and 61 patients (86%) with combined ID were
under 18 years of age, the oldest diagnosed HIES patient was 34
and the oldest combined ID patient was 53.
CVID provides the best example for showing that PID can also
be diagnosed in adult patients, with 457 patients (65%) diagnosed
at or after the age of 18 years. One patient even received his
diagnosis at 79 years of age. Patients who were diagnosed with
PID at a rate between 45 and 49% at 18 and above had selective
IgA deficiency (31 patients), isolated IgG subclass deficiency (45
patients), and unclassified antibody deficiency (111 patients). The
oldest diagnosed patients in this particular group were 75 and 79
years of age (unclassified antibody deficiency) and the oldest was
81 (isolated IgG subclass deficiency).
Amongst all the registered PID patients, 4 different PIDs
were prevalent in patients who were older than 18 at the time
of diagnosis: 2 patients with properdin P factor complement
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FIGURE 6 | Diagnostic delay: (A) diagnostic delay of 527 CVID patients, (B) diagnostic delay of 89 CGD patients, (C) diagnostic delay of 87 agammaglobulinemia
patients, (D) diagnostic delay of 40 SCID patients.
deficiency (PFC) were each 19, 1 patient with mannose-
binding lectin deficiency (MBL) was 41, 1 patient with Steinert
myotonica dystrophia was 44 and the other two were each
59; 2 patients who had thymoma with immunodeficiency
were 47 and 67.
The youngest patient diagnosed within the main
category complement deficiency was 6 years old (a patient
with unclassified complement ID). For more details see
Supplementary Table 45.
Diagnostic Delay
We had a closer look to three different types of delay: (i) general
diagnostic delay, (ii) clinical delay, and (iii) genetic delay. For
information related to general diagnostic delay, data from 1,643
patients were available; namely, the year of symptom onset and
the date of diagnosis (genetic or clinical). We scrutinized these
data in the context of the 12 most prevalent PIDs and speculated
whether the diagnostic delay between the presenting symptoms
and diagnosis had decreased over time. Detailed information
about the general diagnostic delay in 4 of the 12 most prevalent
PIDs is presented in Figure 6. Amongst the 12 most prevalent
PIDs, we observed no significant decrease neither in general
diagnostic delay nor in the clinical diagnostic delay over the last
5 decades.
Data on clinical diagnostic delay were available for 1,596
patients and analysed in the context of the most prevalent
12 PIDs. The longest clinical delay was in CVID, isolated
IgG subclass deficiency, and selective IgA deficiency (average:
around 7 years, median: 3 years), followed by HIES (average:
5.33 years, median 3 years). The lowest median delay was
for DGS (average: 0.96 years) and SCID (average: 0.43 years),
see Table 3.
Data on genetic diagnostic delay were available for 554
patients (the genetic diagnosis was available before the clinical
diagnosis in 14 cases of different PIDs, but none was
made prenatally). Data relative to the 12 most prevalent
PIDs are displayed in Supplementary Table 46. CVID patients
had the highest genetic diagnostic delay (average: 11.08
years, median: 9 years), while DGS patients had the lowest
(average: 0.48 years, median 0 years). The average genetic
delay in SCID patients was 1.42 years and the median
0.5 years.
With regard to genetic diagnostic delay, a significant
improvement was documented in SCID patients (p
= 0.0074), as well as HIES patients (p = 0.037)
(Supplementary Figures 3 and 4). Between 1997 and 2006,
the average genetic diagnostic delay in SCID patients was 2.43
years and the median was 1 year, whereas between 2007 and 2017
the average delay was 1 year and the median was 0.
Deceased Patients
Out of 2,453 patients, 51 patients (2%) were registered as
deceased of whom 14 patients had received HSCT. In 2 of
those 14 patients (aged 5 and 9 years, CGD), the graft vs.
host disease was explicitly documented as cause of death.
Main causes leading to death for the other patients were
mostly respiratory failure (16 patients, 31%) and multiple organ
failure (13 patients, 25%). As underlying cause, infections
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were mentioned for 20 patients (39%). The age of death
ranged between 4 months (surgical complications, multiple
organ failure, CGD) and 88 years (cause of death is unknown,
CVID) (Supplementary Table 47).
TABLE 3 | Average and median of clinical diagnostic delay.
12 PIDs Number of
patients*
Patients with clinical
diagnostic delay
information
Average of
clinical delay
(years)
Median of
clinical
delay (years)
CVID 527 527 7.35 3
Isolated IgG subclass
deficiency
64 64 7.22 3
Selective IgA
deficiency
37 37 6.78 3
Unclassified antibody
deficiency
168 168 5.69 2
HIES 43 42 5.33 3
Combined ID 50 50 4.53 2
Unclassified IDs 49 49 3.96 2
CGD 89 85 3.01 1
A-T 49 47 1.96 1
Agammaglobulinemia 87 80 1.60 1
DGS 38 25 0.96 0
SCID 40 40 0.43 0
Total 1,243 1,216 5.52 2
*Year of onset and year of clinical diagnosis and or genetic diagnosis.
Treatment
Three types of treatment were documented in the registry’s
Level 1 dataset: (i) IgG substitution, (ii) hematopoietic stem cell
transplantation (HSCT), and (iii) gene therapy.
Of the 2,453 registered patients, 1,203 (49%) received IgG
replacement at the date of last news, 850 (35%) did not receive
Ig-replacement and for 400 patients (16%), no information was
available. The main categories with the highest proportion of
patients receiving IgG substitution were predominantly antibody
disorders (71% of 981 patients), followed by defects in innate
immunity (42% of 19 patients), combined immunodeficiencies
(32% of 57 patients), unclassified immunodeficiencies (32%
of 24 patients), and other well-defined PIDs (30% of 86
patients) (Table 4).
More than half (52%) the patients on IgG treatment
had CVID, 12% had an unclassified antibody deficiency, 8%
had agammaglobulinemia, and 5% had isolated IgG subclass
deficiency. Other PIDs were represented by <4% (Table 4).
The share of patients who received IgG replacement
within the respective PID diagnosis was: CVID (87%),
agammaglobulinemia (87%), unclassified syndromic
PID (63%), CSR/HIGM (Hyper-IgM) (58%), IgA with
isolated IgG subclass deficiency (58%), unclassified
antibody deficiency (56%), and isolated IgG subclass
deficiency (56%). All other PIDs comprised of <50% of
patients who had been treated by IgG replacement. IgG
substitution was not registered amongst the following
TABLE 4 | IgG substitution referring to main categories and foremost PIDs.
Main categories/PID Total patient
number
Number of patients receiving
Ig-replacement
Number of patients receiving
Ig-replacement (%)
Percentage out of 1,203 patients
with Ig replacement (%)
Predominantly antibody disorders 1,390 981 71 82
CVID 728 630 87 52
Unclassified antibody deficiency 267 150 56 12
Agammaglobulinemia 112 97 87 8
Isolated IgG subclass deficiency 101 57 56 5
CSR/HIGM (Hyper-IgM) 38 22 58 2
IgA with IgG subclass deficiency 26 15 58 1.2
Defects in innate immunity 45 19 42 2
Combined immunodeficiencies 177 57 33 5
Combined ID 74 33 45 3
SCID 83 20 24 2
Unclassified Immunodeficiencies 76 24 32 2
Other well defined PIDs 283 86 30 7
A-T 66 25 38
HIES 55 20 36 2
Unclassified syndromic PID 16 10 63 1
Diseases of immune dysregulation 136 19 14 2
Phagocytic disorders 199 9 5 0.7
Complement deficiencies 44 2 5 0.2
Autoinflammatory disorders 84 1 1 0.1
No PID entered 19 5 26 0.4
Total 2,453 1,203 49 100
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PIDs (each with more than 10 registered patients):
selective IgA deficiency, congenital neutropenia, FMF,
HAE (C1Inh), TRAPS, and Shwachman-Diamond-
syndrome (Supplementary Table 48).
The IgG substitution delay is defined as the time span
between diagnosis and first IgG treatment. This data was
calculated for 1,189 patients. The time span varied from 20
years prior to the PID diagnosis being established to 53 years
post-diagnosis. Both extremes were observed in CVID patients.
Most patients (666/56%) received their therapy within the
first year of their PID diagnosis being established, while 194
(16%) received therapy within the second year of diagnosis
(Figure 7A, an extract). There were 189 patients (16%) who
received their first IgG treatment prior to clinical or genetic
diagnosis (timespan is between 1 day and up to 20 years before a
PID diagnosis). Further details about these patients can be found
in Supplementary Table 49.
Regarding the route of administration, 844 of patients (70%)
received subcutaneous (sc) IgG infusions, 78 of these patients
with the addition of hyaluronidase; 344 (29%) had intravenous
(iv) infusions of IgG, while 15 patients (1%) had no documented
information about the route of administration.
Amongst the 853 adults (≥18 years old), 261 patients
(31%), and 581 patients (68%) received IgG intravenously
or subcutaneously, respectively; the route of administration
was unknown in 11 patients. Amongst the 350 patients who
underwent IgG substitution below the age of 18, 83 (24%)
received IgG intravenously, while 263 patients (75%) received
it subcutaneously. The route of administration was unknown in
4 children.
We next speculated whether the absolute IgG dose prescribed
per month [g] correlated with the respective PID. We therefore
analysed the 12 major PIDs and PIDs with minimum 7 patients
≥18 years of age in this context: The minimum IgG dose
was between 1 g (CVID) and 35 g (DGS) per month and the
highest dose between 28 g (ATM) and 130 g (CVID). Within
these PIDs groups, the average was between 20 g (ATM) and
49 g (DGS per month, the median between 21 g (ATM) and
43 g (agammaglobulinemia). The total average of these PIDs
was 35 g per month, whereas the total median was 33 g per
month (Table 5).
Out of the 822 adult patients who received Ig substitutions,
most (315) received 25–35 g per month, 149 patients received
40–45 g per month, and 88 patients received 20–25 g per
month (Figure 7B).
To determine the relative replacement dosage in mg IgG per
body weight (kg) per month, the available weight and IgG dosage
data from 1,062 patients were used from the date at last news.
For the sc route, the highest relative doses were between 400 and
450mg per body weight (kg) per month, whereas for the iv route,
there were two peaks, one was between 300 and 400, the other
between 550 and 600mg per kg body weight (kg) per month
(Supplementary Table 50 and Figure 7C). The most prevalent
dosage interval was 400–450mg IgG per body weight (kg) per
month. The average relative dosage was 517mg per body weight
(kg) per month, and the median was 474mg per body weight (kg)
per month.
To determine how often side effects occurred with IgG
substitution, we analysed (i) the general side effects and (ii) the
side effects corresponding to the route of application.
Of the 1,203 patients who had received IgG replacement,
128 patients (11%) had documented side effects, whilst 922
(77%) patients were documented to not have had side effects.
No information on side effects was available for the remaining
153 patients (13%). Local side effects such as rashes and
swelling were recorded for 3 patients undergoing iv replacement
but in 63 patients receiving sc IgG treatment. Headache
was documented in 16 patients receiving iv replacement
and 19 patients receiving sc treatment. Anaphylaxis was
documented in 3 patients receiving iv replacement and in
2 patients receiving sc treatment. Fever was documented in
4 patients receiving iv replacement but did not occur in
patients under sc treatment. Arterial or venous thrombosis,
aseptic meningitis, and renal failures were not reported. In
addition, other rare side effects were entered for 39 patients
(iv: 13, sc: 26): fatigue/tiredness (iv: 3, sc: 10), nausea (iv: 2,
sc: 2), skin induration/scarring (iv: 0, sc: 2), noduli in the
subcutaneous tissue (iv: 0, sc: 2), dizziness when infusion ran too
quickly (iv: 2), and dizziness without further reasons provided
(iv:0, sc:2) (Figure 8A)
We also examined whether a high relative IgG dose per month
had an influence on the occurrence of side effects. Information
on side effects, Ig dose and weight was only available for
1,061 patients under IG replacement therapy. Side effects were
reported in 120 (11%) of these patients. There was no significant
correlation between the dosage and the frequency of side
effects (Supplementary Table 50 and Figure 8B). Furthermore,
whether a patient received subcutaneous vs. intravenous
IgG replacement therapy had no significant bearing on the
occurrence of side effects (Figure 8C).
A total of 334 HSCTs were registered in 300 patients (12% of
all PID patients) between 2004 and June 4, 2017, of which 32
patients had more than one HSCT. Stem cells derived from bone
marrowwas transplanted 233 times (70%), from peripheral blood
81 times (24%), and from cord blood 8 times (2%). The source of
HSCs was not documented in 12 (3%) cases. Most donors were
matched unrelated (MUD) to the patient (163 cases, 49%); in
62 cases (19%) they were matched siblings (MSD); in 70 cases
(21%) they were haplo-identical donors (one of the parents);
and in 16 cases (5%) they were mismatched unrelated donors
(MMUD); in 1 case (0.3%) the patient received autologous stem
cells; in 14 cases (4%) the transplant originated from an “other
related donor”; and in 8 cases (2%) the type of donor was not
registered (Table 6).
Most of the HSCTs were performed in patients from the
main category of combined immunodeficiencies (114 of all
registered CID patients, 64%), followed by phagocytic disorders
(78 patients, 39%), other well-defined PIDs (45 patients,
16%), diseases of immune dysregulation (41 patients, 30%),
predominantly antibody disorders (17 patients, 1%), unclassified
immunodeficiencies (3 patients, 4%), defects in innate immunity
(1 patient, 2%), and autoinflammatory disorders (1 patient, 1%).
None of the 44 patients with complement deficiencies received
an HSCT.
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FIGURE 7 | IgG substitution. (A) IgG substitution delay for 1,115 patients who received IgG replacement in the range of 3 years before PID diagnosis and 12 years
afterwards. (B) Absolute IgG dose per month [g] of 822 patients ≥18 years of age. (C) Relative IgG dose (mg per kg body weight) for 1,062 patients.
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TABLE 5 | Absolute IgG dose for patients ≥18 years of age: minimum, maximum, average, and median (minimum 7 patients get IgG substitution).
PID where minimum 7 patients
above 17 years get IgG treatment
12 PIDs Number of patients
on IgG substitution
Number of patients dose
per month (g) available
Min – Max IgG dose
per month (g)
Average
dose
Median
dose
Agammaglobulinemia x 47 45 22–87 45 43
SCID x 7 7 27–57 39 41
CVID x 546 528 1–130 36 35
Combined ID x 18 15 7–61 35 35
Unclassified antibody def. x 99 95 3–87 34 33
CSR/HIGM (Hyper-IgM) 10 10 11–61 32 30
IgA with IgG subclass deficiency 13 13 7–43 24 28
Isolated IgG subclass deficiency x 43 43 7–91 29 27
Unclassified IDs x 16 14 5–76 29 24
HIES x 8 8 5–35 23 24
ATM x 7 6 14–26 20 21
DGS x 3 3 35–70 49 35
CGD x 0 – – – –
Selective IgA deficiency x 0 – – – –
Total 814 784 1–130 35 33
Most of the 300 patients who had an HSCT were SCID
patients. The relative proportion of patients who underwent an
HSCT are described according to the PIDs as follows: 72 out of
84 SCID patients (86%), where 2 of these patients underwent
additional gene therapy; 61 out of 129 CGD patients (47%); 28
out of 74 patients with combined immunodeficiency (38%); 20
out of 29 patients with Wiskott-Aldrich syndrome (69%); 16 out
of 20 FHLH patients (80%); 11 out of 38 patients (29%) with
CSR/HIGM (Hyper-IgM syndrome); 9 out of 29 XLP patients
(31%); 8 out of 55 HIES patients (15%); and 7 out of 32 patients
congenital neutropenia (22%). HSCTs were also carried out in
3 out of 75 patients (4%) with unclassified immunodeficiency;
in 2 / 267 patients with unclassified antibody deficiency (0.7%);
in 2/112 agammaglobulinemia patients (2%); and in 1/66 A-T
patients (2%). Patients with DGS, selective IgA deficiency, and
isolated IgG subclass deficiency were not treated with an HSCT.
Only 2 out of the 728 CVID patients (0.3%) received an HSCT
(for more details see Supplementary Table 51).
Eighty percent (240) of the HSCT patients had already
received a genetic diagnosis by the time of transplantation. In
60 patients, HSCT was performed without knowledge of the
exact genetic defect. Amongst these 60 patients: the genetic defect
could not be identified in 24 patients, despite genetic testing; the
genetic test results were still pending for 10 patients at the time of
HSCT; 7 patients were marked as not tested, and no information
was given for 19 patients.
The first HSCT in our cohort was performed in 1989. The
second was recorded 3 years later. The frequency of HSCTs
increased steadily from 2 in 1994, to up to 40 in 2013. Since then,
the number of PID-related HSCTs has stabilised to around 25–40
transplantations per year (Figure 9).
We examined whether IgG treatment was still necessary
after an HSCT. Out of the 300 patients who had undergone at
least 1 HSCT, 42 (14%) received IgG replacement after HSCT,
while 188 patients (62%) did not. There was no information
in 69 patients (23%) with regard to IgG substitution after
transplant (for details see Supplementary Table 52). Amongst
the 41 patients who already had IgG treatment before their HSCT,
18 (44%) continued their treatment, whereas 23 patients (56%)
did not. There was no information about 249 patients in terms
of IgG treatment prior to HSCT. Following HSCT, 4 patients
required IgG substitution for the first time: 3 patients between
6 and 9 months later (with XLP, atypical SCID, and unclassified
phagocytic disorders) and 1 SCID patient after 3 years. These
patients each had a different PID. For 13 patients, it could not be
identified whether they shortly after or before their HSCT they
got their IgG substitution as only year and month was given for
both dates (4 persons) or only the year (9 patients).
Out of 298 patients who recieved at least one HSCT, 14 passed
away. Two of them because of graft vs. host disease (compare
section “Deceased patients” above), eight were lost to follow-up,
and 276 are registered as “alive.”
Gene therapy was recorded in 5 patients (0.2%). The first case
of gene therapy was documented in 2002 in an X-linked SCID
patient, the second in 2005 in a GP91-phox CGD patient, the
third and fourth in 2006 in an ADA-SCID and a WAS patient,
respectively. In 2009, the X-linked SCID patient who had been
treated in 2002 had a second gene therapy procedure, and in
2012 an additional WAS patient underwent gene therapy. Gene
therapy was combined or followed-up by HSCT in 2 of the 5
patients: The ADA-SCID patient had a transplant of autologous
bone marrow CD34+ cells engineered with the ADA gene after
non-myeloablative conditioning, the WAS patient who had had
gene therapy in 2006 at the age of almost 4 had an HSCT at the
age of 11. The CGD patient who had gene therapy at the age of 5
had an HSCT at age 10.
We then speculated whether patients who had undergone
gene therapy still needed IgG: the 2 patients with X-linked SCID
and WAS who received gene therapy but no HSCT still received
IgG substitution, despite their gene therapy being successful.
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TABLE 6 | Donor and source of HSCT.
Donor/Source Bone
marrow
Peripheral
blood
Cord
blood
Source
unknown
HSCT
total
%
Matched unrelated (MUD) 124 35 2 2 163 49
Matched sibling (MSD) 56 4 1 1 62 19
Haplo-identical (parent) 30 36 1 3 70 21
Other related donor 12 1 1 14 4
Mismatched unrelated (MMUD) 9 5 2 16 5
Autologous 1 0 0 1 0.3
Unknown 1 0 1 6 8 2
Total 233 68% 81 24% 8 2% 12 3% 334
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FIGURE 9 | 326 HSCTs performed between 1989 and 2016 for 294 patients.
DISCUSSION
PID Registries
Electronic PID registries can be found at different administrative
levels: databases operated by single centres, national registries,
or even international networks such as the ESID registry (5).
Although their datasets differ, almost all these databases store
a common subset of parameters on PID patients similar to the
one covered by Level 1 of the PID-NET registry: PID diagnosis,
basic demographic data, (presenting) symptoms, and treatment7.
Among others, their aim is to identify the prevalence, incidence,
and morbidity of PIDs. Many physicians and researchers
recognize the importance of PID registries (5–8).
Prevalence and Under-Reporting
Since its advent in 2009, the PID-NET registry has grown
continuously from 630 German patients who were registered
by 7 participating centres into the European ESID-Registry,
to a current total of 2,453 patients registered by 36 centres.
7USIDNET. Core Report Form.. Available online at: https://usidnet.org/about-the-
registry/registry-user-resources/data-collection-forms/ and https://usidnet.org/
wp-content/uploads/2014/01/Paper-Registry-2017-Update.pdf (accessed August
14, 2018).
This covers all the major centres that treat PID patients in
Germany. However, since it is not mandatory to register PID
patients into the PID-NET registry, we are only able to report a
minimum prevalence of PID diseases in Germany. The current
data reported here yields a minimum prevalence of 2.72 per
100,000 inhabitants in Germany.
In 2006, the Kuwait National Primary Immunodeficiency
Disorders Registry (KNPIDR) reported a childhood PID
prevalence of 11.98 per 100,000 children (8). Other registries
do not report a specific prevalence in children. In Germany,
the corresponding value was 7.5 per 100,000 children (1,010
patients in 13,538,146 population under 18 years of age)8.
Taking into account the data reported: (i) in 2014 by the Swiss
registry (4.16/100,000) (9), (ii) the study in Olmsted County,
Minnesota (USA) (4.6/100,000) (10), (iii) more recently by
the UKPID registry (5.90/100,000) (11), (iv) the CEREDIH
(France) (8.0/100,000) based on a recent epidemiological study
by Mahlaoui et al. (1), and (v) Iranian Registry (IPIDR)
8Statistisches Bundesamt (Destatis): Bevölkerung: Deutschland, Stichtag, Altersjahre,
Bevölkerung auf Grundlage des Zensus 2011. Available online at: https://www-
genesis.destatis.de/genesis/online/link/tabelleErgebnis/12411-0005/ (accessed July
5, 2017), German.
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(3,92/100.000) (12), we believe that the current report only covers
about one third of PID patients living in Germany. A review
article on 22 states from the Middle East and Northern Africa
(MENA states) reports an overall prevalence between 0.81 to
30.5 per 1,000,000 inhabitants (13). The number of PID patients
in South Africa is estimated to be between 2,850 and 45,728,
although the actual reported number of patients in the SA
registry is currently only 301 (14). The Latin American Society for
Immunodeficiencies (LASID) registry is an international registry
of 15 countries of South America representing 599 million
inhabitants and reports for 2014 on 5,203 living patients (15) and
for 2018 on 7,977 patients (16).
This under-reporting of PID patients into registries might
create a bias; hence, the data presented here need to be
interpreted carefully. This is also true for other registries,
however, only the publication by the IPIDR gives an estimation
on the expected underreporting (2.3% of the expected PID
patients registered) (12).
There are several reasons why not all PID patients are
registered in Germany: The main limiting factor for a complete
documentation of all diagnosed PID patients into the registry
remains the limited man-power for documentation. This is
also true for subsequent quality control (monitoring), which is
currently only possible in Level 2 and Level 3 projects.
Hence, the fewer patients are treated in a centre, the more
likely they are to be completely registered. The number of
physicians and study nurses in relation to the number of patients
also has an important bearing on the quality and completeness of
the respective datasets. Multiple overlapping registries and more
specialized registries—such as the HSCT registries (SCETIDE
and EBMT), and AID-Net—may also be a reason for the non-
registration of PID patients into the PID-NET registry. The
time-consuming ethical approval process deters smaller centres
and local physicians from joining the registry. Patients with a
less-severe PID who are mainly treated with IgG substitutions
to avoid conditions such as infections often prefer to go to
a local physician closer to home. As a possible reason for
underreporting, it could also be suspected that PID patients do
not always give consent for registration. However, according to
personal communications with the treating physicians these cases
are very rare.
The transition from adolescence to adulthood often leads to a
halt in registry documentation, e.g., when the patient leaves the
pediatric department and is treated by a local physician who does
not participate in the project. This is especially true when one
of the few specialized centres that treat adult PID patients is not
within the vicinity.
Apart from the under-reporting of patients already diagnosed
with PID, we assume there is also a substantial number of patients
who are still to be diagnosed. The awareness campaigns that have
been launched within the last few years (e.g., FIND-ID, https://
www.find-id.net) might help to overcome this issue.
Distribution Within the IUIS Categories
The distribution of patients within the main IUIS categories
in the PID-NET registry is similar to that in the UKPID
registry, except in the case of complement deficiency, where the
proportion of registered patients among all patients is 13% in
the UK (11) and only 2% in Germany. This is most likely due to
documentation bias, since HAE patients (C1 deficiency) are seen
by immunologists in the UK, but not in Germany. In contrast
to the PID-NET registry, the UKPID also registers secondary
antibody deficiencies.
The Centre de Référence Déficits Immunitaires Héréditaires
(CEREDIH) runs the PID registry in France. Since CEREDIH
uses an internal classification system based on the PID diagnoses,
and differs from the IUIS classification, we could not directly
compare the distribution among the main categories, e.g., CVID
is categorized as a B-cell deficiency, which is part of the adaptive
PID (17) category.
A similar situation is presented by the Iranian registry
(12). However, the main categories of the Iranian registry
presented do not match to the ESID registry’s categories, e.g.,
“immunodeficiencies affecting cellular and humoral immunity”
is not present in the ESID classification whereas the category
“other well-defined PIDs” is not present in the Iranian register.
LASID registry reports of seven categories: predominantly
antibody deficiencies (65%), other well-defined PIDs (10%),
phagocytic disorders (9%), predominantly T-Cell deficiencies
(9%), complement deficiencies (3%), unclassified IDs (3%), and
immune dysregulation syndromes (1%) (15).
In Switzerland, the main category with the highest difference
to our registry was predominantly antibody disorders, with 62.4%
compared to 57% in Germany (9).The Kuwait registry named six
main categories for their 176 patients: complement deficiencies
(4%, Germany: 2%), diseases of immune dysregulation (7%,
Germany: 6%), predominantly antibody disorders (20%,
Germany: 57%), other well-defined PIDs (25%, Germany: 11%)
(7). However, more autosomal recessive diseases are present in
Kuwait, due to a higher number of consanguineous marriages.
The South African Primary Immunodeficiency Registry (SAPID)
with its 301 registered patients, uses also six categories: antibody
deficiencies (45%), complemenrt deficiencies (29%), combinded
ID (CD) and phagocyte defect (both 6%), syndromes (1,6%),
autoinflammatory (3%), innate defects (2%), unclassified ID
(defined as patients “with a clinical profile of immune deficit
but without any laboratory-demonstrated defect” (1%), and
dysregulation (0.7%) (14).
Moreover, it is unclear whether all publications are based on
the same version of IUIS classification.
The classification of PID is a dynamic process that changes
regularly due to ongoing research. The ESID classification is
based on the IUIS classification. However, since IUIS publishes
a new version of the PID classification every two years, it is
continuous work in progress to align the ESID classification with
the IUIS. We try to keep up with the modifications of the IUIS
classification but the actual implementation in the ESID registry
naturally lags behind. The current classification presented in
this manuscript therefore has no one to one representation
in an IUIS classification. For example, the PID-NET registry
followed a suggestion by the IUIS to rename the main categories,
whereby “predominantly T-cell deficiencies” were subordinated
under “combined immunodeficiencies,” and “autoimmune and
immune dysregulation syndromes” are now listed as “diseases
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of immune dysregulation.” Furthermore, the 2014 re-design of
the registry with the introduction of clinical diagnostic working
criteria led, in some cases, to changes in PID diagnoses; thus,
the current distribution of main categories cannot be directly
compared to those published before the re-design (18).
PID Distribution
The distribution of PID regarding to the year of diagnosis was
influenced by the first published description of the respective PID
and the discovery of the disease-causing mutation. For example,
the first report of A-T was in 1926, but cloning and identification
of the ATM gene was only published in 1995 (19). The DGS
causing microdeletion Del 22q11.2 was found 1981. The genes
defects causing HIES were only identified in 2007 (STAT3) and
2009 (DOCK8). A specific PID diagnosis can only be assigned
when the PID was described and published before. With the
introduction of the new diagnostic ESID-registry criteria for PID,
the PID-NET registry has now implemented a more uniform
classification system for PID, leading to more consistency in the
registration of diagnoses.
Genetic Testing
To date, there is no system in place that offers regular,
widespread genetic testing in Germany. Genetic tests were not
performed in most of the CVID patients, unclassified PIDs,
isolated IgG subclass deficiency, and selective IgA deficiency
(Supplementary Table 34). This might be due to the fact that the
patient’s PID diagnosis was considered to be already clear to the
physician based on clinical and laboratory results and therefore
a genetic confirmation of the PID diagnosis will not have an
effect of the patient’s further treatment. Another reason for not
testing everybody are the still high costs. Genetic analysis was
performed in 168 patients by targeted gene sequencing, but the
suspected disease-causing mutation was not found. However, the
proportion of PID patients who do have a genetically-confirmed
diagnosis is increasing: whereas only about 31.2% of all patients
in the PID-NET registry had a genetic diagnosis in March 2012
(4), this number increased to 36.4% by July 2017. Other registries
report a similar percentage of genetically-confirmed diagnoses
[France: 40% (17), Russia: 36% (20), Iran 33.1% (12)]; in the
Kuwait registry, a PID-causing mutation was found in 53% of the
264 patients (21). This indicates that genetic testing is becoming
an increasingly important component in the work-up of PID
patients. But who should be tested? For example, at the PID
reference centre in Freiburg, all patients with a suspected PID
undergo genetic testing, given that the management plan always
changes with a genetically-confirmed diagnosis.
Presenting Symptoms
While 74% of all PID patients with presenting symptoms
had infections, a substantial proportion of patients (25%)
presented with immune dysregulation. Therefore, PID should
be suspected in any patient with immune dysregulation.
The ranking of presenting symptoms in the South African
registry (ASID) was similar with regard to infections as
most prevalent symptom, followed by autoimmunity features
(14). However, due to a different classification, the precise
numbers cannot be directly compared. The Iranian registry
classified the presenting symptoms based on the affected
organ (12). Thus, a direct comparison is again difficult.
However, infections are frequently presented among the
listed entities.
Age Distribution
In the most recent report of the UKPID registry, 17% of patients
(807) were 16 years or younger (11), whereas in Germany
the number of registered PID patients aged 16 or under was
42% (947 patients). In 2014, the proportion of patients in
the Swiss National Registry for PID who were younger than
18 was 31% (109 living patients from 348 patients) (9), in
the US-American USIDNET it was 25% out of 3,459 patients
(6) whereas in Germany, the corresponding percentage was
45% (1,010 living patients). This indicates that in the PID-
NET registry, paediatric patients are considerably more strongly
represented in comparison to the British, Swiss andUS-American
registries. This might also be due to the fact, that there are
only a few centres in Germany which focus on treating adult
PID patients.
Diagnostic Delay
InGermany, there are the guidelines of API (Arbeitsgemeinschaft
Pädiatrische Immunologie e.V.) and DGfI (Deutschen
Gesellschaft für Immunologie) for the diagnosis of PID9.
However, the registry does not ask for the fulfilment of theses
formal criteria of the pathological susceptibility to infections, but
the first clinical symptoms suggestive of a PID as based on the
physician’s judgement.
Comparison of the diagnostic delay with other registries can
be difficult, since the exact definition of “diagnostic delay” is
missing (11) or is different to the criteria used in this publication.
The Kuwait registry defines diagnostic delay as time between
the “initial presentation” of the patient and the definitive PID
diagnosis (8), whereas CEREDIH uses the timespan between
birth and diagnosis, resulting in a median diagnostic delay
of 6 years in CVID and 1 year in agammaglobulinemia (17).
The median diagnostic delay for CVID patients in Switzerland
was also 6 years (9), whereas in the UK it was 4 years (11),
and in Germany 3 years. The median diagnostic delay for
agammaglobulinemia patients was 1 year in the UK (11) and <1
year in Germany.
The reason why some PID patients only manifest late in
their lives may either lie in the variable expressivity of their
respective mutation (e.g., as seen in ADA1), in the fact that a
PID-predisposing condition needs to be triggered by a specific
infection (e.g., EBV in XLP), or that the PID is not primarily
monogenetic but has an epigenetic component (22).
IgG Substitution
The median IgG dosage for CVID patients in Sweden (90
patients) and Germany (568 patients) was similar: 500mg per kg
9Susan Farmand, Ulrich Baumann, Horst von Bernuth, Michael Borte et al.
Leitlinie: Diagnostik auf Vorliegen eines primären Immundefekts. AWMF. Available
online at: https://www.awmf.org/leitlinien/detail/ll/112-001.html (accessed March
7, 2019), German.
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body weight per month in Sweden (23) and 481mg per kg body
weight per month in the PID-NET registry.
According to the Swedish PIDcare registry, of the 566 patients
who had received IgG substitution by the end of September 2017,
9.4%were treated intravenously, 84.1% subcutaneously, and 6.5%
intramuscularly10. This compares to 29% intravenously and 70%
subcutaneously in Germany. Other registries did not report the
relative proportions of sc vs. iv therapy.
Documentation of severe side effects due to IgG substitution
was rarely observed. In Germany, 5 out of the 128 patients (11%)
with side effects had anaphylaxis. There may also be a bias in
documentation due to way the physician communicates with the
patient; for example, if the physician states that a little swelling
or induration is normal, the patient might not report it as a side
effect at all. Other registries did not report any side effects from
immunoglobulin replacement.
CONCLUSION AND OUTLOOK
The medical care of PID in Germany differs in contrast to
some other countries in such as there is no real nationwide
coverage of medical care in the field of clinical immunology. The
medical care for adults are restricted to only very few centres
whereas for patients under 18 years (with a mainly genetically
diagnosed PID), the medical care takes place in many children
hospitals. The German PID-NET registry is a precious tool for
physicians, researchers, the pharmaceutical industry, politicians,
and ultimately the patients, for whom the new medical and
political outcomes will eventually lead to better understanding in
PID, a more timely diagnosis and better treatment.
In order to make the registry even more powerful, we suggest
addressing the following items for improving the data entry
process at hospitals: motivation program for physicians and
study nurses, incentives for participation (e.g., own statistics),
additional staff for research purposes, closer collaboration
between participating and not yet participating departments
within and between hospitals, as well as with potential financial
backers. Additional personnel (e.g., an additional documenting
specialist to support the growing number of centres) would also
provide a significant level of help in fostering the documenting
process. Furthermore, the implementation of additional
departments that monitor PID patients should be promoted.
In addition to these general measures, another aim is to extend
the Level 1 dataset covered by the registry by providing more
detailed information on malignancies and the use of biologicals,
and entering additional laboratory values. However, substantial
long-term funding is ultimately needed in order to achieve
these aims.
10PIDcare. Resultat och statistik sedan registret startades.Available online at: http://
pidcare.se/wp-content/uploads/2017/07/Redovisning-kvartal-3.pdf (accessed
November 19, 2018), Swedish.
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